Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
09/2000
09/05/2000US6114338 Heterocyclic compounds
09/05/2000US6114333 2-Pyrimidineamine derivatives and processes for their preparation
09/05/2000US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists
09/05/2000US6114317 Method of locking 1α-OH of vitamin D compounds in axial orientation
09/05/2000US6113942 Pharmaceutical composition for piperidinoalkanol compounds
09/05/2000US6113918 Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
09/05/2000US6113917 Genetic polypeptides added to ceramide based lipid-glycan anchor structure
09/05/2000US6113901 Immunopotentiating cd-3 antigen monoclonal antibodies
09/05/2000US6113900 Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders
09/05/2000US6113899 Antagonists of chaperonin 10
09/05/2000US6113898 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
09/05/2000CA2116442C Novel glycosphingolipids and the use thereof
08/2000
08/31/2000WO2000050641A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
08/31/2000WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease
08/31/2000WO2000050607A2 Goodpasture antigen binding protein
08/31/2000WO2000050597A2 Neutrokine-alpha and neutrokine-alpha splice variant
08/31/2000WO2000050577A1 Drug design based on the structure of lta4 hydrolase
08/31/2000WO2000050562A2 Dna encoding snorf25 receptor
08/31/2000WO2000050461A1 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
08/31/2000WO2000050460A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050408A1 Pyridazin-3-one derivatives and medicines containing the same
08/31/2000WO2000050081A1 Product and method for treatment of conditions associated with receptor-desensitization
08/31/2000WO2000050080A1 Compositions and methods using complexes of calreticulin and antigenic molecules
08/31/2000WO2000050078A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
08/31/2000WO2000050077A1 Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
08/31/2000WO2000050073A2 Caulobacter lps immunoadjuvant
08/31/2000WO2000050071A1 PROTEIN OmpA OF KLEBSIELLA PNEUMONIAE ASSOCIATED WITH THE HCG HORMONE OR A COMPOUND INVOLVED IN CELL PROLIFERATION OR FERTILITY
08/31/2000WO2000036113A3 Extending graft survival by heme oxygenase-i expression induced immunomodulation
08/31/2000WO2000032632A3 Allo- and auto-reactive t-cell epitopes from rhesus protein and their use
08/31/2000WO2000020601A9 Polyketide synthase enzymes and recombinant dna constructs therefor
08/31/2000WO2000018795A9 Compositions and methods for wt1 specific immunotherapy
08/31/2000CA2689696A1 Microemulsions with adsorbed macromolecules and microparticles
08/31/2000CA2366688A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
08/31/2000CA2364160A1 Product and method for treatment of conditions associated with receptor-desensitization
08/31/2000CA2363641A1 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
08/31/2000CA2363637A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363146A1 Caulobacter lps immunoadjuvant
08/31/2000CA2363118A1 Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
08/31/2000CA2363112A1 Neutrokine-alpha and neutrokine-alpha splice variant
08/31/2000CA2362906A1 Dna encoding snorf25 receptor
08/31/2000CA2362533A1 Gene sequence variations with utility in determining the treatment of disease
08/31/2000CA2362099A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection
08/30/2000EP1031348A2 Interleukin-4 production inhibitors
08/30/2000EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers
08/30/2000EP1031346A1 Noninvasive vaccination through the skin
08/30/2000EP1030911A1 Human aspartic proteases
08/30/2000EP1030865A2 Th2 CELL DEPLETION; COMPOSITIONS; METHODS
08/30/2000EP1030862A1 Viral clearance process
08/30/2000EP1030851A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
08/30/2000EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity
08/30/2000EP1030842A1 Metalloproteinase inhibitors
08/30/2000EP1030836A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
08/30/2000EP1030684A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
08/30/2000EP1030662A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
08/30/2000EP1030661A1 N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA 2? INHIBITORS
08/30/2000EP0759937B1 Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
08/30/2000EP0671946B1 Immunoreactive peptides from epstein-barr virus
08/30/2000EP0668772B1 Specific immune system modulation
08/30/2000CN1265149A Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
08/30/2000CN1265148A Anticoagulant fusion protein anchored to cell membrane
08/30/2000CN1265112A Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
08/30/2000CN1265038A Cellular vesicle called 'exosome', prepn. and use thereof in immune stimulation
08/30/2000CN1264583A Active aloe powder and preparing process thereof
08/30/2000CN1055921C Derivative of vitamin D system which is modified in 20-position, prepn. of same and pharmaceutical made of same
08/30/2000CN1055833C Prepn. method immunity and strengthen nutriious liquid
08/29/2000US6111084 Sialyl lewis mimetics produced by solid phase synthesis; antiinflammatory agents
08/29/2000US6111074 Amino acid sequence of polypeptide from the uridine monophosphate kinase family; for screening bactericides and bacteriostats; for diagnosis and prophylaxis of infections
08/29/2000US6110964 For treating arthritis, inflammatory bowel disease, crohn's disease, emphysema, acute respiratory distress syndrome, asthma chronic obstructive pulmonary disease, alzheimer's disease, organ transplant toxicity, cachexia, cancer
08/29/2000US6110941 Compounds analogous to thalidomide from the class comprising piperidine-2,6-diones
08/29/2000US6110939 As a substance p antagonists treating tachykinin-mediated disease, asthma, central nervous system disorder
08/29/2000US6110933 Amino acid derivatives and their use as phospholipase A2 inhibitor
08/29/2000US6110929 Immunomodulators which induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor and inhibit t-helper-type 2 immune response; for treatment of viral and neoplastic diseases
08/29/2000US6110923 Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
08/29/2000US6110922 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
08/29/2000US6110919 Diazabicyclic neurokinin antagonists
08/29/2000US6110910 Antiinflammatory agents, antiarthritic agents, antirheumatic agents, anticarcinogenic agents
08/29/2000US6110899 LICC of Streptococcus pneumoniae
08/29/2000US6110896 Peptidyl compounds and their therapeutic use
08/29/2000US6110747 Compounds and methods for modulating tissue permeability
08/29/2000US6110466 Modified plant viruses as vectors
08/24/2000WO2000049409A2 ASSAY FOR THE IDENTIFICATION OF IgE ANTIBODY SUPPRESSORS
08/24/2000WO2000049153A1 Fucosyl transferase gene
08/24/2000WO2000049144A2 Pyk2 binding proteins
08/24/2000WO2000049137A2 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell
08/24/2000WO2000049045A1 Peptide variants of the tumour marker muc1 and the use thereof
08/24/2000WO2000049015A1 Pyridine compounds and their pharmaceutical use
08/24/2000WO2000048989A1 Mevinolin derivatives
08/24/2000WO2000048643A1 Biodegradable, injectable oligomer-polymer composition
08/24/2000WO2000048638A2 Multi-mutant diphtheria toxin vaccines
08/24/2000WO2000048631A2 Adjuvant and cell maturation agent
08/24/2000WO2000048629A1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS
08/24/2000WO2000048628A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response
08/24/2000WO2000048625A2 Inhibitors for use in hemostasis and immune function
08/24/2000WO2000048623A1 Novel amide derivatives as growth hormone secretagogues
08/24/2000WO2000048616A1 High molecular weight extracts of $i(convolvulus arvensis )(field bindweed)
08/24/2000WO2000048610A1 Chemical compounds
08/24/2000WO2000048609A1 Chemical compounds
08/24/2000WO2000048591A1 Combinations for the treatment of diseases involving angiogenesis
1 ... 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 ... 1172